Neuromodulation and female sexual function: Does treatment for refractory voiding symptoms have an added benefit?

Michael Ingber, Ibrahim A. Ibrahim, Kim A. Killinger, Ananias C. Diokno, Kenneth M. Peters

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction and hypothesis: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). Methods: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. Results: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). Conclusions: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.

Original languageEnglish (US)
Pages (from-to)1055-1059
Number of pages5
JournalInternational Urogynecology Journal
Volume20
Issue number9
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Interstitial Cystitis
Overactive Urinary Bladder
Therapeutics
Databases
Population

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Urology

Cite this

Ingber, Michael ; Ibrahim, Ibrahim A. ; Killinger, Kim A. ; Diokno, Ananias C. ; Peters, Kenneth M. / Neuromodulation and female sexual function : Does treatment for refractory voiding symptoms have an added benefit?. In: International Urogynecology Journal. 2009 ; Vol. 20, No. 9. pp. 1055-1059.
@article{be482b74169c4ac89354009bcad6cf9a,
title = "Neuromodulation and female sexual function: Does treatment for refractory voiding symptoms have an added benefit?",
abstract = "Introduction and hypothesis: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). Methods: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. Results: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). Conclusions: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.",
author = "Michael Ingber and Ibrahim, {Ibrahim A.} and Killinger, {Kim A.} and Diokno, {Ananias C.} and Peters, {Kenneth M.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s00192-009-0900-3",
language = "English (US)",
volume = "20",
pages = "1055--1059",
journal = "International Urogynecology Journal and Pelvic Floor Dysfunction",
issn = "0937-3462",
publisher = "Springer London",
number = "9",

}

Neuromodulation and female sexual function : Does treatment for refractory voiding symptoms have an added benefit? / Ingber, Michael; Ibrahim, Ibrahim A.; Killinger, Kim A.; Diokno, Ananias C.; Peters, Kenneth M.

In: International Urogynecology Journal, Vol. 20, No. 9, 01.01.2009, p. 1055-1059.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neuromodulation and female sexual function

T2 - Does treatment for refractory voiding symptoms have an added benefit?

AU - Ingber, Michael

AU - Ibrahim, Ibrahim A.

AU - Killinger, Kim A.

AU - Diokno, Ananias C.

AU - Peters, Kenneth M.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Introduction and hypothesis: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). Methods: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. Results: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). Conclusions: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.

AB - Introduction and hypothesis: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). Methods: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. Results: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). Conclusions: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.

UR - http://www.scopus.com/inward/record.url?scp=70350450720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350450720&partnerID=8YFLogxK

U2 - 10.1007/s00192-009-0900-3

DO - 10.1007/s00192-009-0900-3

M3 - Article

C2 - 19440647

AN - SCOPUS:70350450720

VL - 20

SP - 1055

EP - 1059

JO - International Urogynecology Journal and Pelvic Floor Dysfunction

JF - International Urogynecology Journal and Pelvic Floor Dysfunction

SN - 0937-3462

IS - 9

ER -